Family Legacy Inc. Acquires Shares of 2,766 Thermo Fisher Scientific Inc. $TMO

Family Legacy Inc. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,766 shares of the medical research company’s stock, valued at approximately $1,387,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Legacy Wealth Managment LLC ID raised its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares in the last quarter. Allied Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $26,000. High Note Wealth LLC grew its holdings in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the period. Swiss RE Ltd. purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $28,000. Finally, JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.3%

Shares of TMO opened at $586.62 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $531.72 and a 200-day simple moving average of $508.48. The stock has a market cap of $216.90 billion, a price-to-earnings ratio of 31.56, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Finally, KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock worth $30,643,589 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.